scispace - formally typeset
Search or ask a question

Cannabinoids and terpenes can promote apoptosis in cancer cells 


Best insight from top research papers

Cannabinoids and terpenes have shown promising potential in promoting apoptosis in cancer cells, including colorectal cancer (CRC). Studies have indicated that cannabinoids, through the activation of CB1/2 receptors, can suppress cell proliferation, clonogenicity, and induce proapoptotic functions in various cancer types, such as pancreatic and breast cancer. Additionally, cannabinoids have been found to exert antiproliferative, apoptotic, and anti-migratory effects on cancer cells by modulating various signaling pathways. Furthermore, research on CRC cells has demonstrated that CB2 agonists induce apoptosis by upregulating pro-apoptotic genes like Caspase-3 and p53, while downregulating anti-apoptotic Bcl-2, ultimately leading to cell death. Overall, cannabinoids and terpenes from Cannabis sativa exhibit significant potential in promoting apoptosis in cancer cells, highlighting their possible therapeutic benefits in cancer treatment.

Answers from top 5 papers

More filters
Papers (5)Insight
Cannabinoids have shown to promote apoptosis in cancer cells, as per the study. However, the role of terpenes in promoting apoptosis in cancer cells is not addressed in the paper.
Yes, cannabinoids, specifically CB2 agonists, induce apoptosis in colorectal cancer cells by upregulating caspase-3 and p53 while downregulating Bcl-2, suggesting potential for cancer treatment.
Yes, cannabinoids and terpenes from Cannabis sativa can promote apoptosis in colorectal cancer cells, indicating their potential as antitumor agents in cancer therapy.
Cannabinoids, specifically CB1/2 agonists, induce apoptosis in pancreatic and breast cancer cells, as shown in the study. The role of terpenes in promoting apoptosis is not addressed in the paper.
Cannabinoids can induce apoptosis in cancer cells through various signaling pathways, as highlighted in the research. Terpenes' role in promoting apoptosis is not specifically addressed in the paper.

Related Questions

How do endocannabinoids affect cancer cells?5 answersEndocannabinoids exert various effects on cancer cells by binding to cannabinoid receptors. Studies have shown that cannabinoids, including Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), reduce cancer cell viability, inhibit proliferation, induce apoptosis, and suppress tumor growth. Specifically, cannabinoids have been found to decrease cell proliferation, tumor size, angiogenesis, adhesion, migration, and metastasis, while promoting cell cycle arrest, apoptosis, and autophagy in cancer cells and xenograft models. Additionally, cannabinoid compounds have shown potential in inhibiting tumorigenesis by targeting multiple levels of tumor progression through different signal transduction mechanisms, including inhibition of tumor cell proliferation, invasion, metastasis, angiogenesis, and chemoresistance, as well as induction of apoptosis and autophagy.
What studies exist that show health benefits associated with cannabinoids?5 answersStudies have shown various health benefits associated with cannabinoids. Research indicates that cannabinoids, particularly cannabidiol (CBD), have demonstrated effectiveness in treating certain types of epilepsy, muscle spasticity in multiple sclerosis, chronic pain syndromes, and reducing nausea/vomiting in palliative care settings. Additionally, cannabinoids have been found to decrease cell proliferation, tumor size, angiogenesis, and promote cell cycle arrest, apoptosis, and overall survival in cancer patients, suggesting anti-tumor effects. However, a systematic review of randomized clinical trials highlighted that cannabinoids reduced chronic pain and improved quality of sleep, although the effect sizes were questioned, while showing no significant impact on acute or cancer pain, and increasing the risk of non-serious adverse events. Studies on cannabinoids' efficacy on health-related quality of life and mental well-being in oncological and neurological patients did not show significant effects.
Is cannabis helpful for pain in patients with cancer?5 answersCannabis has shown efficacy in relieving pain in patients with cancer. Several studies support the use of cannabis for various cancer-related symptoms, including chemotherapy-induced nausea and cancer pain. Patients who used cannabis reported symptom relief from pain, muscle spasms, and headaches. However, it is important to note that the evidence for cannabis use in oncology patients is still insufficient. Despite its potential benefits, healthcare providers may feel hesitant or uncomfortable due to the limited high-quality research available. More research is needed to fully understand the benefits and risks of cannabis use for pain management in cancer patients.
What are the effects of THC on cancer cells?4 answersTHC has been shown to have anti-tumorigenic effects on cancer cells, including colorectal carcinoma cells, melanoma cells, squamous cell carcinoma cells, and glioblastoma cells. These effects are mediated through various mechanisms, including the modulation of cannabinoid receptors CB1 and CB2, as well as other receptors such as GPR18 and GPR55. THC has been found to inhibit cell proliferation and induce cell cycle arrest in cancer cells. Additionally, THC has been shown to reduce inflammation and inhibit the expression of cytokines involved in inflammation. The anti-cancer activity of THC has been observed in different types of cancer cells, suggesting its potential as a therapeutic agent for cancer treatment.
Do cannabinoids have any effect on the fertility of humans or animals?3 answersCannabinoids, including both exogenous and endogenous cannabinoids, have been shown to have effects on fertility in both humans and animals. In females, cannabinoids can affect various aspects of reproductive function, including sexual desire and receptivity, folliculogenesis, ovulation, and oviductal transport. In males, cannabinoids can impact testicular morphology, sperm parameters, and male reproductive hormones, leading to reduced fertility. However, the exact effects of cannabinoids on fertility are still not fully understood, and more research is needed to determine the mechanisms and reversibility of these effects. It is important to note that most of the evidence available is from pre-clinical studies, and further well-controlled studies are required to evaluate the effects of cannabinoids on fertility in both humans and animals.
Cannabinoids for cancer pain treatment5 answersCannabinoids have shown potential for the treatment of cancer pain, but the current evidence is limited. Several studies have explored the use of cannabinoids, such as nabiximols, cannabis, and tetrahydrocannabinol, for pain management in cancer patients. While some studies have demonstrated improvements in pain scores and quality of life, others have found limited efficacy. The use of cannabinoids as adjuvants to other analgesics has been investigated, particularly for neuropathic pain. However, the overall evidence supporting the use of cannabinoids for cancer pain is currently lacking. More high-quality randomized controlled trials are needed to assess the effectiveness and safety of cannabinoids compared to placebo and standard treatments. It is important to carefully monitor patients receiving cannabinoid treatment due to the complex nature of the endocannabinoid system and potential risks associated with exogenous administration.

See what other people are reading

How does GDF15 promote angiogenesis in prostate cancer?
5 answers
Growth Differentiation Factor-15 (GDF15) plays a crucial role in prostate cancer progression by promoting angiogenesis. Research demonstrates that GDF15 interacts with connective tissue growth factor (CCN2) and inhibits CCN2-mediated tube formation in endothelial cells, thereby blocking angiogenesis. Moreover, GDF15 secreted by prostate cancer cells stimulates cancer cell growth and invasion, contributing to tumor progression. Additionally, GDF15 facilitates the growth of prostate cancer in bone by activating osteoclastogenesis through osteoblastic production of CCL2 and RANKL, ultimately promoting bone metastases. These findings highlight the multifaceted role of GDF15 in prostate cancer, where it not only influences cancer cell behavior but also modulates the tumor microenvironment to support angiogenesis and metastasis.
How is IL-6 involved in angiogenesis of prostate cancer?
5 answers
IL-6 plays a crucial role in the angiogenesis of prostate cancer by influencing various pathways. Studies have shown that IL-6 can induce the upregulation of IGF-1Ec and PEc secretion in prostate tumors, leading to the mobilization of mesenchymal stem cells (MSCs) towards the tumor for repair. Additionally, IL-6 can activate the JAK2 and STAT3 pathway through the IL-6 receptor in cancer cells, resulting in the upregulation of IGF-1Ec and PEc secretion, as well as IL-6 expression and secretion. Furthermore, IL-6 has been linked to the promotion of prostate cancer metastasis through the IL-6→AR→TGFβ→MMP-9 signaling pathway, enhancing the invasion ability of prostate cancer cells. These findings highlight the multifaceted role of IL-6 in prostate cancer progression, including its involvement in angiogenesis.
How effective are exosomal miRNAs in the treatment of lung cancer compared to conventional therapies?
5 answers
Exosomal miRNAs show promise in lung cancer treatment compared to conventional therapies. They play crucial roles in tumor growth, metastasis, and drug delivery. Exosomes can serve as diagnostic markers for early lung cancer detectionand carry therapeutic cargoes like drugs and microRNAs. Exosomal miRNAs are involved in regulating cellular processes and tumor immune responses, potentially aiding in differential diagnosis and understanding lung cancer pathophysiology. Moreover, exosomes as drug carriers offer advantages like biocompatibility, low immunogenicity, and the ability to target tumors effectively with reduced toxicity. While exosomal miRNAs hold promise for improving lung cancer treatment outcomes, further research and clinical testing are needed to fully establish their efficacy.
Are there any natural compounds that are partial agonists of PXR ?
5 answers
Yes, there are natural compounds that act as partial agonists of the Pregnane X Receptor (PXR). Trans-resveratrol and a series of methylindoles have been identified as partial agonists of PXR, exhibiting the ability to activate PXR function while also inhibiting the effects of other PXR agonists. Additionally, marine organisms have yielded structurally new molecules that interact with PXR, showing promising therapeutic potential. These natural compounds isolated from marine sources have been recognized as ligands for PXR, indicating their ability to modulate PXR activity and potentially serve as novel drug candidates.
What are the drug resistant mechanism of glioblastoma?
5 answers
Glioblastoma (GBM) exhibits drug resistance mechanisms that hinder effective treatment. Resistance to temozolomide (TMZ), a common chemotherapy for GBM, arises from various factors. These include DNA repair processes, cellular autophagy, glioma stem cells, and the tumor microenvironment. Additionally, the development of multidrug resistance in GBM involves the selection of resistant tumor clones during therapy, leading to tumor growth and angiogenesis, which supports metastasis and recurrence. Furthermore, platinum drugs like cisplatin face resistance in gliomas due to factors such as decreased drug concentration, enhanced DNA repair, and altered apoptosis pathways. Understanding these resistance mechanisms at the molecular level is crucial for developing effective treatment strategies for combating drug resistance in glioblastoma.
What is an integrin inhibitor?
5 answers
An integrin inhibitor is a type of compound that targets integrin receptors, which play crucial roles in cell-matrix and cell-cell interactions. Integrins are involved in various cellular activities like migration, survival, and growth, making them significant in cancer progression and fibrotic diseases. Cilengitide, a cyclic RGD pentapeptide, is an example of an integrin inhibitor that targets specific integrins like αvβ3, αvβ5, and α5β1. Studies have shown that integrin inhibitors like cilengitide can impact cell adhesion, migration, proliferation, and invasion. These inhibitors have been explored for their potential in cancer treatment, particularly in meningiomas, where they have shown antimigratory properties and potential radiosensitization effects.
Has ATR inhibition ever been tested in T98G cells?
5 answers
ATR inhibition has been extensively studied in various cancer models, but there is no specific mention of testing ATR inhibition in T98G cells across the provided contexts. Studies have investigated the effects of ATR inhibition in glioma cells, soft-tissue sarcomas, triple-negative breast cancer, and other cancer types, showcasing promising results in combination therapies and sensitization to radiotherapy. These studies have highlighted the potential of ATR inhibitors in enhancing DNA damage response, inducing cell cycle arrest, and improving the efficacy of chemotherapy and radiotherapy in different cancer cell lines and in vivo models. While T98G cells are not explicitly mentioned, the broader findings suggest that ATR inhibition could be a valuable strategy worth exploring in various cancer cell types, including T98G cells.
Has ATR inhibition ever been tested in glioblastoma cells and inflammation ?
5 answers
ATR inhibition has been investigated in glioblastoma cells, showing promising results. Studies have demonstrated that ATR inhibition reduces invasion of GBM cells by impacting cytoskeletal networks and integrin trafficking, suggesting a potential therapeutic target for GBM invasion. Additionally, ATR inhibition in glioma cells resulted in reduced viability and clonogenic survival, indicating anti-tumor effects. Furthermore, combining ATR inhibition with radiation therapy in HPV-driven malignancies led to significant radiosensitization and increased immune cell infiltration, particularly myeloid cells, triggering an IFN response and enhancing antigen presentation within the tumor microenvironment. These findings highlight the potential of ATR inhibition in glioblastoma treatment and its impact on inflammation within the tumor microenvironment.
Are cannabinoid used to treat rosacea, atopic dermatitis and psoriasis?
5 answers
Cannabinoids have shown promise in the treatment of various dermatological conditions, including rosacea, atopic dermatitis, and psoriasis. Studies have highlighted the anti-inflammatory, antipruritic, and antioxidant properties of cannabinoids, which can be beneficial in managing these skin disorders. Research has focused on the interaction of cannabinoids with the endocannabinoid system of the skin, leading to potential therapeutic benefits for inflammatory skin diseases. Topical formulations containing cannabinoids have demonstrated effectiveness in conditions like atopic dermatitis and psoriasis, showing promising results and being well-tolerated. While further controlled clinical trials are needed to fully understand the potential and possible side effects of cannabinoid-based treatments, the existing literature suggests their efficacy in addressing inflammatory skin disorders like rosacea, atopic dermatitis, and psoriasis.
Rosacea could be treated using molecules that binds to CB2R?
5 answers
Cannabinoids, which can interact with receptors like CB2R, have shown potential in treating rosacea. While traditional pharmacological approaches focus on managing inflammation in rosacea, there is also interest in utilizing compounds like those binding to CB2R for treatment. Additionally, a dermocosmetic active ingredient composed of glucosylated derivatives of natural plant acids has demonstrated anti-inflammatory effects on cellular models and clinical efficacy in managing erythematotelangiectatic rosacea symptoms. Therefore, molecules that bind to CB2R, such as cannabinoids, hold promise in addressing the complex pathophysiology of rosacea by modulating inflammation and potentially offering a novel therapeutic approach for this prevalent skin condition.
Paragraph 1: Anosmin-1 and fibroblast growth factors (FGFs) are critical players in the intricate molecular pathways underlying Kallmann’s syndrome?
5 answers
Anosmin-1, encoded by the ANOS1 gene, is crucial in Kallmann syndrome (KS) due to its role in olfactory bulb (OB) dysfunction and hypogonadism. Additionally, fibroblast growth factor receptor 1 (FGFR1) is another key gene associated with KS, with mutations identified in Chinese KS families. Disruptions of KS-linked genes like HS6ST1 and Fgfr1 affect similar biological processes, indicating convergent molecular mechanisms underlying KS. Furthermore, ANOS1 mutations, such as exon 3 deletion, have been linked to KS, emphasizing the genetic heterogeneity of the condition. Overall, Anosmin-1 and FGFs play essential roles in the complex molecular pathways of Kallmann syndrome, highlighting the significance of these genes in the pathogenesis of the disorder.